News Archive

A book icon

Publications: Week of August 27, 2024

Tuesday, August 27, 2024
Featuring: Laila Dahmoush, MBChB, Rachel Fitzjerrells, BS, Ashutosh Mangalam, PhD
Microscope icon

Under the Scope: August 2024

Friday, August 16, 2024
August's recipients include: Lisa Blake, Matthew Krasowski, and Heather West.
Dr. Karandikar and Dr. Rogers

Dr. Kai Rogers Receives a Grant Award through the NIH R25/UE5 Program

Sunday, August 11, 2024
Dr. Kai Rogers, a resident in the Pathology physician-scientist training program (PSTP), has received an NIH/NINDS grant award through its R25/UE5 funding mechanism. The University of Iowa R25/UE5 program, entitled “Carver College of Medicine Clinical Neuroscientist Training Program (CNS-TP)” is led by Drs. George Richerson and Kumar Narayanan in the Department of Neurology. This program acknowledges the critical need for physicians to be involved in basic research on human brain disease and provides direct support toward this goal. It provides funding for residents in any department if their research is in any area aligned with the goals of the NINDS. Its major purpose is to increase the number of physicians performing disease-oriented neuroscience research, and to decrease the time for physician-scientists to obtain independent funding (K Awards, R01s, etc.).
Stephanie

Research on Intravital Imaging of Influenza-specific Lung T Resident Memory by Stephanie van de Wall, Scott Anthony, Lisa Hancox and Lecia Epping in the Harty Lab was Recently Published in Immunity

Friday, August 9, 2024
Stephanie van de Wall, Ph.D. was the lead author of the study. Co-authors include Scott Anthony, Lisa Hancox and Lecia Epping from the Harty lab, Vladimir P. Badovinac Ph.D., also from U. Iowa Pathology as well as Ryan Langlois (U. Minnesota) and Dietmar Zehn (Technical University of Munich). The work was supported by grants from the NIH to VPB and JTH.
Dr. Harty

Dr. John Harty Receives Five-Year R01 Research Grant from the National Institutes of Health Investigating Why Malaria Vaccines are Less Effective in Malaria Endemic Regions

Friday, July 5, 2024
Dr. Harty received a new five-year grant from the NIH entitled “Mechanisms of compromised CD8 T cell responses to vaccination in malaria experienced hosts.” The award totals $3,442,760, the project started June 24, 2024 and concludes April 30, 2029.
Nastaran Daneshgar holding a cake

Nastaran Daneshgar Successfully Defends and Publishes her Ph.D. Thesis

Friday, July 5, 2024
Nastaran Daneshgar successfully defended her doctoral thesis in early June and graduated from the Experimental Pathology Ph.D. Program. Her thesis, Klotho-Sirt1-CHK2 Pathways in the Regulation of Cardiac Function in Aging and Post-Myocardial Injury, focuses on aging and cardiac function, offering promising insights into potential therapeutic interventions for age-related cardiac diseases. She conducted her thesis work in the laboratories of Dr. Dao-Fu Dai and Dr. Chad Grueter, utilizing a combination of human tissue, mouse models, and human-derived stem cell models.
Microscope icon

Under the Scope: June 2024

Monday, June 17, 2024
June's recipients include: Dion Baylor, Bob Rotzoll, and Junalyn Vander Pol.
Dr. Harty

Dr. John Harty Receives Two-Year R21 Research Grant from the National Institutes of Health Investigating the Impact of Brain Residing T Cells on the Function of Brain Resident Microglia and Dendritic Cells

Monday, June 17, 2024
Dr. Harty received a new 2 year grant from the NIH entitled “Brain T cell interactions in microbial experienced mice.” The award totals $404,300, the project started June 4, 2024 and concludes April 30, 2026.
Dr. Offer

Genetic Factors can Increase the Risk of a Toxic Reaction to Certain Cancer Drugs

Monday, May 6, 2024
Cancer researcher Steven Offer, PhD investigates the genetic factors that increase the risk of a toxic reaction to the cancer drug Fluorouracil (5-FU). 5-FU, used since the 1970s to treat many cancers including colorectal, stomach, breast and cervical cancer, can be toxic to certain patients. While many cancer drugs can be toxic, what sets 5-FU apart is that severe illness and death is largely preventable.
Dr. Hefti

Dr. Marco Hefti receives a five-year R01 research grant from the National Institutes of Health investigating the tau protein’s role during neurodevelopment

Wednesday, May 1, 2024
Dr. Marco Hefti received a five-year NIH R01 award entitled “A non-canonical role for tau in early human brain development” from the National Institute of Neurological Disorders and Stroke. The award totals $561,007 and the project starts May 1, 2024 and concludes February 28, 2029.